Genmab A/S (OCSE:GMAB) 3-Year Revenue Growth Rate : 17.70% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Genmab A/S 3-Year Revenue Growth Rate?

Genmab A/S's Revenue per Share for the three months ended in Mar. 2024 was kr63.10.

During the past 12 months, Genmab A/S's average Revenue per Share Growth Rate was 16.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 17.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 36.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 38.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Genmab A/S was 326.80% per year. The lowest was -20.40% per year. And the median was 34.45% per year.

Competitive Comparison of Genmab A/S's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Genmab A/S's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab A/S's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Genmab A/S's 3-Year Revenue Growth Rate falls into.

Genmab A/S 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Genmab A/S (OCSE:GMAB) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Genmab A/S 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Genmab A/S's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (OCSE:GMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OCSE:GMAB) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.